Nektar Therapeutics (NKTR) Earnings Date, Estimates & Call Transcripts $1.11 -0.05 (-4.31%) (As of 09/26/2024 ET) Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Earnings SummaryUpcoming Earnings DateNov. 5EstimatedActual EPS (Aug. 8) -$0.25 Missed By -$0.04 Consensus EPS (Aug. 8) -$0.21 Conference Call TranscriptConference Call AudioEarnings Press Release Get Nektar Therapeutics Earnings AlertsEnter your email address below to receive the latest news and earnings results for NKTR and its competitors with MarketBeat's FREE daily newsletter. Skip Charts & View Estimated and Actual Earnings DataEarnings Per ShareRevenueNKTR Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.NKTR Estimated and Actual Revenue by Quarter Estimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad Genesis Gold GroupKamala’s tax plan is worse than you think—find out whyBuffett's been eerily quiet about his reasons, but his actions speak volumes. When someone with his track record starts pulling out of the market, it's time to pay attention.Get your FREE, no-obligation Wealth Protection Guide now Nektar Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateCompany GuidanceQ1 20242($0.22)($0.20)($0.21) Q2 20242($0.22)($0.18)($0.20) Q3 20242($0.23)($0.18)($0.21) Q4 20242($0.26)($0.24)($0.25) FY 20248($0.93)($0.80)($0.87) Q1 20251($0.19)($0.19)($0.19) Q2 20251($0.18)($0.18)($0.18) Q3 20251($0.18)($0.18)($0.18) Q4 20251($0.27)($0.27)($0.27) FY 20254($0.82)($0.82) ($0.82)NKTR Earnings Date and InformationNektar Therapeutics last announced its quarterly earnings data on August 8th, 2024. The biopharmaceutical company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.21) by $0.04. The company earned $23.49 million during the quarter, compared to the consensus estimate of $17.24 million. Nektar Therapeutics has generated ($0.92) earnings per share over the last year (($0.92) diluted earnings per share). Earnings for Nektar Therapeutics are expected to grow in the coming year, from ($0.85) to ($0.69) per share. Nektar Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, November 5th, 2024 based off prior year's report dates.Read More Nektar Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueLinks 11/5/2024(Estimated)------- 8/8/2024Q2 2024($0.21)($0.25)($0.04)($0.25)$17.24 million$23.49 million 5/9/2024Q1 2024($0.21)($0.18)+$0.03($0.17)$14.91 million$21.64 million 3/4/2024Q4 2023($0.21)($0.22)($0.01)($0.22)$17.09 million$23.89 million 11/7/2023Q3 2023($0.18)($0.19)($0.01)($0.14)$20.68 million$24.14 million 8/8/2023Q2 2023($0.30)($0.27)+$0.03($0.27)$20.94 million$20.50 million 5/9/2023Q1 2023($0.26)($0.25)+$0.01$0.23$20.60 million$21.59 million Get the Latest News and Ratings for NKTR and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Nektar Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 2/28/2023Q4 2022($0.43)($0.32)+$0.11($0.32)$22.21 million$22.02 million11/3/2022Q3 2022($0.47)($0.24)+$0.23($0.17)$23.31 million$23.63 million8/4/2022Q2 2022($1.01)($0.85)+$0.16($0.85)$22.75 million$21.59 million 5/5/2022Q1 2022($0.72)($0.49)+$0.23($0.49)$24.89 million$24.82 million2/28/2022Q4 2021($0.81)($0.79)+$0.02($0.79)$25.33 million$25.00 million 11/4/2021Q3 2021($0.80)($0.70)+$0.10($0.70)$27.94 million$24.92 million 8/5/2021Q2 2021($0.72)($0.69)+$0.03($0.69)$26.42 million$28.33 million 5/6/2021Q1 2021($0.72)($0.68)+$0.04($0.68)$26.15 million$23.60 million 2/25/2021Q4 2020($0.68)($0.65)+$0.03($0.65)$19.64 million$23.46 million 11/5/2020Q3 2020($0.80)($0.61)+$0.19($0.61)$22.82 million$30.00 million 8/6/2020Q2 2020($0.69)($0.45)+$0.24($0.45)$22.76 million$48.85 million 5/7/2020Q1 2020($0.77)($0.53)+$0.24($0.28)$46.88 million$50.57 million 2/27/2020Q4 2019($0.69)($0.64)+$0.05($0.64)$26.74 million$33.90 million 11/6/2019Q3 2019($0.73)($0.56)+$0.17($0.56)$26.42 million$29.22 million Nektar Therapeutics Earnings - Frequently Asked Questions When is Nektar Therapeutics's earnings date? Nektar Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, November 5th, 2024 based off last year's report dates. Learn more on NKTR's earnings history. Did Nektar Therapeutics beat their earnings estimates last quarter? In the previous quarter, Nektar Therapeutics (NASDAQ:NKTR) missed the analysts' consensus estimate of ($0.21) by $0.04 with a reported earnings per share (EPS) of ($0.25). Learn more on analysts' earnings estimate vs. NKTR's actual earnings. How can I listen to Nektar Therapeutics's earnings conference call? The conference call for Nektar Therapeutics's latest earnings report can be listened to online. Listen to Conference Call How can I read Nektar Therapeutics's conference call transcript? The conference call transcript for Nektar Therapeutics's latest earnings report can be read online. Read Transcript How much revenue does Nektar Therapeutics generate each year? Nektar Therapeutics (NASDAQ:NKTR) has a recorded annual revenue of $93.16 million. How much profit does Nektar Therapeutics generate each year? Nektar Therapeutics (NASDAQ:NKTR) has a recorded net income of -$276.06 million. NKTR has generated -$0.92 earnings per share over the last four quarters. What is Nektar Therapeutics's EPS forecast for next year? Nektar Therapeutics's earnings are expected to grow from ($0.85) per share to ($0.69) per share in the next year. More Earnings Resources from MarketBeat Related Companies: ADCT Earnings Date MCRB Earnings Date AVIR Earnings Date PCRX Earnings Date OMER Earnings Date ASMB Earnings Date CPIX Earnings Date AGIO Earnings Date ALKS Earnings Date KRTX Earnings Date Earnings Tools: Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country: U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Australia Earnings Reports Latest Articles: Micron Stock Soars as AI Demand Fuels Big Q4 Earnings BeatGameStop: Earnings Won’t Save It, Dilution Points to TroubleIs Merck Stock Undervalued After Its Colossal Earnings Growth?Polestar Lives to Fight Another Day After Q2 EarningsWhy NVIDIA’s Earnings Point to a Bullish Future for Pure StorageDoes A&F's Q2 Earnings Win Point to a Strong Holiday Season?Salesforce Beats Earnings, Raises Full-Year Profit Outlook This page (NASDAQ:NKTR) was last updated on 9/27/2024 by MarketBeat.com Staff From Our PartnersMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredWhat I believe the Bible says about investing..Greed leads to lying, cheating and stealing to fill an endless appetite for more. And as my friend and trus...Prosperity Research | SponsoredBuffett Dumps $982 Million in BofA Stock—What Does He Know?Buffett's been eerily quiet about his reasons, but his actions speak volumes. When someone with his track reco...Genesis Gold Group | Sponsored[Urgent!] Web3 Could Send One Crypto SoaringVenture Capital corporations and blockchain funds are pouring money into Web3 gaming. And there's one littl...Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredAlex's "Next Magnificent Seven" StocksToday Alex Green is releasing his new breakdown of AI's "Next Magnificent Seven." So please make some time ...The Oxford Club | SponsoredThe Great AI Election of 2024Former House Speaker Nancy Pelosi made 20 times her salary trading Nvidia (NVDA) stock. A recent report out...Chaikin Analytics | SponsoredFed Triggers Boom: Buy this Play on Elon’s New AIHave you seen Elon Musk's new invention? I was already very bullish on this new type of AI. And now that...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nektar Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share Nektar Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.